Ypsomed Completes the Sale of Ypsomed Diabetes Care to TecMed AG Montag, 04. August 2025 - 09:44

Media Release

Ypsomed Completes the Sale of Ypsomed Diabetes Care to TecMed AG

Burgdorf, August 4, 2025, 7:00 AM – Ypsomed Holding AG (SIX: YPSN) announced today that it has successfully completed the sale of its Ypsomed Diabetes Care business to TecMed AG.

The sale of the diabetes care business, initially announced on April 22, 2025, has now been completed. This is a strategic milestone for Ypsomed as it refocuses on its market-leading position in subcutaneous self-injection solutions for pharmaceutical and biotech companies. 

The company also confirms the usual transitional service agreements and certain contract manufacturing services will remain in effect following the transaction closing, ensuring continuity of services and a smooth transition.

Contact

Sam Ghezelbash, Head of M&A and IR, Ypsomed Holding AG 
+41 76 228 51 45, sam.ghezelbash@ypsomed.com 

This communication and the media material can be found at www.ypsomed.com/pressreleases

Ypsomed Group

Ypsomed is the leading developer and manufacturer of injection systems for the self-administration of liquid medication. As the reliable partner of pharmaceutical and biotech companies for more than 40 years, Ypsomed provides tailored selfcare solutions to meet specific needs. Backed by a proven track record, Ypsomed offers the most comprehensive and innovative platform portfolio for pens, autoinjectors, and on-body devices. Delivered with best-in-class execution and ready to integrate with digital health services, these solutions help simplify therapy and improve the quality of life for millions of people living with chronic conditions. Ypsomed is headquartered in Burgdorf, Switzerland, and operates a global network of manufacturing facilities. More than 2,000 employees worldwide are committed every day to making selfcare simpler and easier.
www.ypsomed.com